Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
5.9K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

2.0K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
2.0K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

827
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
827
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.0K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.0K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ILD with datopotamab deruxtecan combinations: a warning signal we should not ignore.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

<i>Aspergillus</i> serology for chronic pulmonary aspergillosis diagnosis: optimization of an enzyme-linked immunosorbent assay kit and assessment of a Western blot kit performance.

Journal of clinical microbiology·2026
Same author

Integrative and interactive genomic analyses guiding personalized combined therapy improve clinical benefit in metastatic patients: A monocentric real-life experience.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.

Cancer cell·2026
Same author

Non-<i>fumigatus Aspergillus</i>-associated pulmonary events: a diagnostic challenge.

Journal of clinical microbiology·2026
Same author

The STING HAQ haplotype and clinical non-penetrance in COPA syndrome.

The Journal of experimental medicine·2026

Related Experiment Video

Updated: Mar 27, 2026

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

429

[Pulmonary sarcomatoid carcinoma].

Martine Antoine1, Thibault Vieira2, Vincent Fallet2

  • 1Service d'anatomie pathologique, hôpital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris cedex 20, France; ER2 et GRC theranoscan, faculté de médecine Pierre-et-Marie-Curie, université Paris 6, 91-105, boulevard de l'Hôpital, 75013 Paris, France.

Annales De Pathologie
|January 19, 2016
PubMed
Summary
This summary is machine-generated.

Pulmonary sarcomatoid carcinomas, a rare non-small cell lung cancer (NSCLC) subtype, exhibit aggressive behavior and poor prognosis. This review details their pathology, molecular features, and potential therapeutic avenues.

Keywords:
Biologie moléculaire/Carcinome bronchique non à petite celluleCarcinome bronchique non à petite celluleCarcinomes sarcomatoïdesEpithelial to mesenchymal transitionMolecular biology/non-small cell carcinomaNon-small cell carcinomaSarcomatoid carcinomaTherapy/non-small cell carcinomaTraitement/Carcinome bronchique non à petite celluleTransition épithélio-mésenchymateuse

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K

Related Experiment Videos

Last Updated: Mar 27, 2026

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

429
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K

Area of Science:

  • Oncology
  • Pathology

Background:

  • Pulmonary sarcomatoid carcinomas (PSCs) are rare non-small cell lung cancers (NSCLCs), comprising ~1% of NSCLC diagnoses.
  • Defined by the 2015 WHO classification, PSCs feature a sarcomatous component and include subtypes like pleomorphic, spindle cell, giant cell carcinomas, carcinosarcoma, and pulmonary blastoma.

Purpose of the Study:

  • To provide a comprehensive pathological description of PSCs.
  • To review existing literature on PSCs, focusing on molecular features.
  • To explore potential new therapeutic strategies for these aggressive tumors.

Main Methods:

  • Literature review of pulmonary sarcomatoid carcinomas.
  • Analysis of pathological characteristics.
  • Review of molecular features and clinical data.

Main Results:

  • PSCs are often voluminous, peripherally located, and show strong FDG uptake on PET-CT.
  • These tumors frequently metastasize to atypical visceral locations.
  • PSCs demonstrate high aggressivity and chemoresistance, leading to a poorer prognosis compared to other NSCLC subtypes.

Conclusions:

  • Pulmonary sarcomatoid carcinomas are aggressive lung cancers with distinct pathological and molecular features.
  • Understanding these characteristics is crucial for improving diagnosis and developing targeted therapies.
  • Further research into molecular pathways, such as epithelial to mesenchymal transition, may reveal novel treatment options.